December 2005

Intralesional Immunotherapy for Genital Warts

Author Affiliations

Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Dermatol. 2005;141(12):1606-1607. doi:10.1001/archderm.141.12.1606

Intralesional immunotherapy employing skin test (recall) antigens derived from mumps, Candida, and Trichophyton is an effective and safe treatment for verruca vulgaris and verruca plana.1,2 In adults, we have shown individual treated wart response rates of 60% to 74% (saline control, 22%) and complete clearing of uninjected anatomically distinct and distant warts in 49% to 71% (saline control, 16%). In children with treatment-resistant warts (2 modalities), complete response rates were 47% and 34%, respectively.3

First Page Preview View Large
First page PDF preview
First page PDF preview